Boosting document time to market with a platform approach

Commercial

It’s an exciting time to be part of the life sciences industry. Innovation is advancing at an unprecedented pace, with life sciences companies developing new modalities for treating diseases. Breakthroughs like CAR-T therapies, CRISPR gene editing, and multiple approaches to precision medicine are offering innovative ways to treat or even cure illnesses. As a result, life expectancy continues to rise [1], and some thought leaders believe we may achieve “longevity escape velocity” before the end of the decade [2].

A significant shift in recent years has been the move from best-of-breed solutions to platform-based approaches. With the rise of AI, life sciences companies are increasingly recognizing the value of consolidating their data onto a single platform. The ability to analyze large datasets is proving far more valuable than relying on isolated point solutions that might only meet specific needs.

Moreover, the traditional business-to-business relationship between life sciences companies and healthcare professionals (HCPs) is evolving. Many companies are now incorporating patients into their ecosystems. Platforms must, therefore, support not only relationships with HCPs but also interactions with patients – starting from clinical trial participation through to market access and patient support programs. Integrating patient data into these ecosystems unlocks valuable insights. Companies leading the way in creating unified data views will be better positioned to respond faster to market demands, identify patients sooner, and significantly improve patient outcomes.

This integration of patients and HCPs into a unified platform also expands the potential of AI. Imagine generative AI (GenAI) capabilities embedded directly into workflows, unnoticeably assisting at every stage of the process and driving efficiencies across the board. This could dramatically shorten the timeline from molecule discovery to market. For example, GenAI could automatically draft a submission dossier for regulatory authorities, leveraging the available data and documents in the ecosystem. By eliminating the need for manual file assembly, this could significantly reduce submission timelines. Through its AI partnership program, Veeva enables companies like BASE life science to configure assistants that can perform such tasks with just a click of a button.

Another area ripe for efficiency gain is translation. While AI isn’t yet ready to replace agencies entirely, it can streamline the global-to-local process, allowing users to work seamlessly within documents in their own language. Whether it’s summarizing complex information in layman’s terms in your native language or translating documents into English, GenAI can complete these tasks in minutes – tasks that would otherwise take companies weeks of back-and-forth with external agencies. Such efficiency gains are unprecedented and crucial to tackling today’s challenges and ensuring that we continue to increase the number of curable diseases.

Want to know more?

If you’re interested in how we can support you, reach out to our experts today. We are happy to guide you on your journey.